Intersect ENT Competitors

Axonics Modulation Technologies (NASDAQ:AXNX) and Intersect ENT (NASDAQ:XENT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Axonics Modulation Technologies and Intersect ENT's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Axonics Modulation Technologies and Intersect ENT, as reported by MarketBeat.

Axonics Modulation Technologies presently has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Intersect ENT has a consensus target price of $23.4286, suggesting a potential upside of 14.34%. Given Intersect ENT's higher probable upside, analysts plainly believe Intersect ENT is more favorable than Axonics Modulation Technologies.

Risk & Volatility

Axonics Modulation Technologies has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares Axonics Modulation Technologies and Intersect ENT's gross revenue, earnings per share and valuation.

Intersect ENT has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

84.2% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 84.3% of Intersect ENT shares are held by institutional investors. 25.7% of Axonics Modulation Technologies shares are held by insiders. Comparatively, 3.5% of Intersect ENT shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Intersect ENT beats Axonics Modulation Technologies on 8 of the 14 factors compared between the two stocks.

Intersect ENT (NASDAQ:XENT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Intersect ENT and Inovio Pharmaceuticals, as provided by MarketBeat.

Intersect ENT presently has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Inovio Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 94.95%. Given Inovio Pharmaceuticals' higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Intersect ENT.

Valuation & Earnings

This table compares Intersect ENT and Inovio Pharmaceuticals' revenue, earnings per share and valuation.

Intersect ENT has higher revenue and earnings than Inovio Pharmaceuticals. Intersect ENT is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intersect ENT and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.3% of Intersect ENT shares are owned by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. 3.5% of Intersect ENT shares are owned by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Intersect ENT has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Summary

Intersect ENT beats Inovio Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Profitability

This table compares GenMark Diagnostics and Intersect ENT's net margins, return on equity and return on assets.

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. Comparatively, 84.3% of Intersect ENT shares are owned by institutional investors. 3.3% of GenMark Diagnostics shares are owned by insiders. Comparatively, 3.5% of Intersect ENT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares GenMark Diagnostics and Intersect ENT's top-line revenue, earnings per share and valuation.

Intersect ENT has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for GenMark Diagnostics and Intersect ENT, as provided by MarketBeat.

GenMark Diagnostics presently has a consensus price target of $22.0125, suggesting a potential downside of 8.24%. Intersect ENT has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Given Intersect ENT's stronger consensus rating and higher probable upside, analysts plainly believe Intersect ENT is more favorable than GenMark Diagnostics.

Silk Road Medical (NASDAQ:SILK) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

84.3% of Intersect ENT shares are owned by institutional investors. 7.8% of Silk Road Medical shares are owned by company insiders. Comparatively, 3.5% of Intersect ENT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Silk Road Medical and Intersect ENT's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Silk Road Medical and Intersect ENT, as reported by MarketBeat.

Silk Road Medical presently has a consensus target price of $61.75, suggesting a potential upside of 23.16%. Intersect ENT has a consensus target price of $23.4286, suggesting a potential upside of 14.34%. Given Silk Road Medical's stronger consensus rating and higher probable upside, analysts plainly believe Silk Road Medical is more favorable than Intersect ENT.

Risk and Volatility

Silk Road Medical has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Valuation & Earnings

This table compares Silk Road Medical and Intersect ENT's top-line revenue, earnings per share (EPS) and valuation.

Intersect ENT has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Summary

Silk Road Medical beats Intersect ENT on 9 of the 14 factors compared between the two stocks.

Intersect ENT (NASDAQ:XENT) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Profitability

This table compares Intersect ENT and Alphatec's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Intersect ENT and Alphatec's gross revenue, earnings per share (EPS) and valuation.

Intersect ENT has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Intersect ENT and Alphatec, as reported by MarketBeat.com.

Intersect ENT currently has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Alphatec has a consensus price target of $15.4286, suggesting a potential downside of 12.34%. Given Intersect ENT's higher probable upside, analysts plainly believe Intersect ENT is more favorable than Alphatec.

Insider & Institutional Ownership

84.3% of Intersect ENT shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 3.5% of Intersect ENT shares are held by company insiders. Comparatively, 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Intersect ENT has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.

Summary

Alphatec beats Intersect ENT on 8 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Luminex and Intersect ENT's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Luminex and Intersect ENT's revenue, earnings per share (EPS) and valuation.

Luminex has higher revenue and earnings than Intersect ENT. Luminex is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Luminex and Intersect ENT, as provided by MarketBeat.

Luminex presently has a consensus price target of $38.00, suggesting a potential upside of 15.33%. Intersect ENT has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Given Luminex's stronger consensus rating and higher probable upside, equities research analysts plainly believe Luminex is more favorable than Intersect ENT.

Risk and Volatility

Luminex has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 84.3% of Intersect ENT shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 3.5% of Intersect ENT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Luminex beats Intersect ENT on 11 of the 14 factors compared between the two stocks.